Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
- PMID: 34848673
- PMCID: PMC8647456
- DOI: 10.12659/MSM.935624
Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
Abstract
In 2021, data from global disease monitoring and infection surveillance programs have shown that vaccination programs have reduced the incidence of SARS-CoV-2 infection and hospitalization and mortality rates. Currently, the US Centers for Disease Control and Prevention (CDC) identifies a fully vaccinated individual as being ≥14 days after the completion of all the recommended doses of a COVID-19 vaccine that has been authorized by the US Food and Drug Administration (FDA). A partially vaccinated individual is <14 days following primary vaccination or has not completed the vaccination program. Clinical studies and data on the vaccine status of populations have identified breakthrough COVID-19 cases in fully vaccinated individuals at 14 or more days after completing the recommended dose of an authorized SARS-CoV-2 vaccine. This Editorial presents an update on what has been learned in the past year on SARS-CoV-2 vaccine responses and breakthrough COVID-19.
Conflict of interest statement
References
-
- Centers for Disease Control and Prevention (CDC) COVID-19. Reporting breakthrough cases. Available from: https://www.cdc.gov/coronavirus/2019-ncov/php/hd-breakthrough.html.
-
- Centers for Disease Control and Prevention (CDC) COVID-19. The possibility of COVID-19 illness after vaccination: Breakthrough infections. Updated Nov 9, 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-mea....
-
- Centers for Disease Control and Prevention (CDC) Hospitalization surveillance network. COVID-NET. Available from: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covid-net/purpose-m....
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
